(MedPage Today) — A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial…
Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114673
Author :
Publish date : 2025-03-15 17:43:00
Copyright for syndicated content belongs to the linked Source.
